Evidence map›Paper›PMID 26984723›Full record

ArticleJournal of virology2016

Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.

Anne-Laure Favier, Evelyne Gout, Olivier Reynard, Olivier Ferraris, Jean-Philippe Kleman, Viktor Volchkov, Christophe Peyrefitte, Nicole M Thielens

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. The Journal of general virology · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. In the Crosshairs: RNA Viruses OR Complement?Frontiers in immunology · 2020
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Anne-Laure FavierUnité de Virologie, Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France favier03al@yahoo.fr.
Evelyne GoutUniversité Grenoble Alpes, Grenoble, France.
Olivier ReynardMolecular Basis of Viral Pathogenicity, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111-CNRS UMR5308, Université Lyon 1, ENS de Lyon, Lyon, France.
Olivier FerrarisUnité de Virologie, Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France.
Jean-Philippe KlemanUniversité Grenoble Alpes, Grenoble, France.
Viktor VolchkovMolecular Basis of Viral Pathogenicity, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111-CNRS UMR5308, Université Lyon 1, ENS de Lyon, Lyon, France.
Christophe PeyrefitteUnité de Virologie, Institut de Recherche Biomédicale des Armées, Brétigny-sur-Orge, France.
Nicole M ThielensUniversité Grenoble Alpes, Grenoble, France.
CEA Grenoble · FRCentre International de Recherche en Infectiologie · FRCentre National de la Recherche Scientifique · FRInserm · FRInstitut de Biologie Structurale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledEbola virus infection requires the surface viral glycoprotein to initiate entry into the target cells. The trimeric glycoprotein is a highly glycosylated viral protein which has been shown to interact with host C-type lectin receptors and the soluble complement recognition protein mannose-binding lectin, thereby enhancing viral infection. Similarly to mannose-binding lectin, ficolins are soluble effectors of the innate immune system that recognize particular glycans at the pathogen surface. In this study, we demonstrate that ficolin-1 interacts with the Zaire Ebola virus (EBOV) glycoprotein, and we characterized this interaction by surface plasmon resonance spectroscopy. Ficolin-1 was shown to bind to the viral glycoprotein with a high affinity. This interaction was mediated by the fibrinogen-like recognition domain of ficolin-1 and the mucin-like domain of the viral glycoprotein. Using a ficolin-1 control mutant devoid of sialic acid-binding capacity, we identified sialylated moieties of the mucin domain to be potential ligands on the glycoprotein. In cell culture, using both pseudotyped viruses and EBOV, ficolin-1 was shown to enhance EBOV infection independently of the serum complement. We also observed that ficolin-1 enhanced EBOV infection on human monocyte-derived macrophages, described to be major viral target cells,. Competition experiments suggested that although ficolin-1 and mannose-binding lectin recognized different carbohydrate moieties on the EBOV glycoprotein, the observed enhancement of the infection likely depended on a common cellular receptor/partner. In conclusion, ficolin-1 could provide an alternative receptor-mediated mechanism for enhancing EBOV infection, thereby contributing to viral subversion of the host innate immune system. IMPORTANCE: A specific interaction involving ficolin-1 (M-ficolin), a soluble effector of the innate immune response, and the glycoprotein (GP) of EBOV was identified. Ficolin-1 enhanced virus infection instead of tipping the balance toward its elimination. An interaction between the fibrinogen-like recognition domain of ficolin-1 and the mucin-like domain of Ebola virus GP occurred. In this model, the enhancement of infection was shown to be independent of the serum complement. The facilitation of EBOV entry into target host cells by the interaction with ficolin-1 and other host lectins shunts virus elimination, which likely facilitates the survival of the virus in infected host cells and contributes to the virus strategy to subvert the innate immune response.

Indexed as

AnimalsCell LineChlorocebus aethiopsComplement System ProteinsEbolavirusFicolinsHEK293 CellsHumansLectinsMacrophagesMannose-Binding LectinMembrane GlycoproteinsMucinsMutationProtein BindingProtein Interaction Domains and MotifsComplement System ProteinsFicolinsLectinsMannose-Binding LectinMembrane GlycoproteinsMucinsViral Envelope Proteins

Identifiers

PMID26984723
PMCPMC4934759
OpenAlexW2301768668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.